Publications

Park K, Dalton JT, Narayanan R, Barbieri CE, Hancock ML, Bostwick DG, Steiner MS, Rubin MA.  2014.  TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.. J Clin Oncol. 32(3):206-11.

Boysen G, Barbieri CE, Prandi D, Blattner M, Chae S-S, Dahija A, Nataraj S, Huang D, Marotz C, Xu L et al..  2015.  SPOP mutation leads to genomic instability in prostate cancer.. Elife. 4

Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, Nataraj S, Deonarine LD, Augello MA, Sailer V et al..  2017.  SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.. Cancer Cell. 31(3):436-451.

Baca SC, Prandi D, Lawrence MS, Mosquera JMiguel, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M et al..  2013.  Punctuated evolution of prostate cancer genomes.. Cell. 153(3):666-77.

Esgueva R, Park K, Kim R, Kitabayashi N, Barbieri CE, Dorsey PJ, Abraham C, Banerjee S, Leung RA, Tewari AK et al..  2012.  Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium.. Diagn Mol Pathol. 21(2):61-8.

Barbieri CE, Rubin MA.  2015.  Genomic rearrangements in prostate cancer.. Curr Opin Urol. 25(1):71-6.

Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat J-P, White TA, Stojanov P, Van Allen E, Stransky N et al..  2012.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.. Nat Genet. 44(6):685-9.

Barbieri CE, Chinnaiyan AM, Lerner SP, Swanton C, Rubin MA.  2016.  The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.. Eur Urol.

Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS.  2016.  DNA Repair in Prostate Cancer: Biology and Clinical Implications.. Eur Urol.